- Home
- RVNC
as 12-20-2024 4:00pm EST
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE |
| Market Cap: | 320.5M | IPO Year: | 2014 |
| Target Price: | $8.45 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $9.75 | Next Earning Date: | 11-07-2024 |
| Revenue: | $256,945,000 | Revenue Growth: | 25.82% |
| Revenue Growth (this year): | 11.28% | Revenue Growth (next year): | 27.21% |
Stock Insider Trading Activity of Revance Therapeutics Inc. (RVNC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hollander David | RVNC | CMO & Global Therapeutics Lead | Nov 18 '24 | Sell | $4.17 | 3,908 | $16,296.36 | 104,945 |
Latest Revance Therapeutics Inc. News
RVNC Breaking Stock News: Dive into RVNC Ticker-Specific Updates for Smart Investing
TipRanks
9 days ago
Revance receives acquisition offer from Crown Laboratories for $3.10 per share
MT Newswires
10 days ago
Revance Therapeutics Board Recommends Stockholders Tender Shares to Crown Laboratories
PR Newswire
10 days ago
Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share
MT Newswires
13 days ago
Sector Update: Health Care Stocks Edge Higher Monday Afternoon
MT Newswires
13 days ago
Revance Therapeutics, Crown Laboratories Reduce Tender Offer Price Amid Teoxane Dispute
Reuters
13 days ago
Revance agrees to lower take-private offer by Crown Labs
Business Wire
13 days ago
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Zacks
a month ago
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates
Compare RVNC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RVNC Revance Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.